The estimated Net Worth of Bradley G Lorimier is at least $40.2 Thousand dollars as of 25 April 2013. Bradley Lorimier owns over 31,964 units of Atyr Pharma Inc stock worth over $40,223 and over the last 16 years Bradley sold LIFE stock worth over $0.
Bradley has made over 5 trades of the Atyr Pharma Inc stock since 2011, according to the Form 4 filled with the SEC. Most recently Bradley exercised 31,964 units of LIFE stock worth $2,355,747 on 25 April 2013.
The largest trade Bradley's ever made was exercising 31,964 units of Atyr Pharma Inc stock on 25 April 2013 worth over $2,355,747. On average, Bradley trades about 10,218 units every 94 days since 2009. As of 25 April 2013 Bradley still owns at least 21,170 units of Atyr Pharma Inc stock.
You can see the complete history of Bradley Lorimier stock trades at the bottom of the page.
Bradley's mailing address filed with the SEC is 5791 VAN ALLEN WAY, , CARLSBAD, CA, 92008.
Over the last 16 years, insiders at Atyr Pharma Inc have traded over $27,288,922 worth of Atyr Pharma Inc stock and bought 966,653 units worth $5,761,237 . The most active insiders traders include James C Blair, Gregory T Lucier, and Craig J Mundie. On average, Atyr Pharma Inc executives and independent directors trade stock every 22 days with the average trade being worth of $34,257. The most recent stock trade was executed by Jill Marie Broadfoot on 31 May 2024, trading 5,000 units of LIFE stock currently worth $8,950.
atyr pharma (nasdaq: life) is engaged in the discovery and clinical development of innovative medicines for patients suffering from severe rare diseases using its knowledge of physiocrine biology, a newly discovered set of physiological modulators. the company's lead candidate, resolaris™, is a first-in-class intravenous protein therapeutic for the treatment of rare myopathies with an immune component. resolaris is currently in a phase 1b/2 clinical trial in adult patients with facioscapulohumeral muscular dystrophy (fshd); a phase 1b/2 trial in adult patients with limb girdle muscular dystrophy (lgmd) 2b or fshd; and a phase 1b/2 trial in patients with an early onset form of fshd. to protect this pipeline, atyr built an intellectual property estate comprising 70 issued or allowed patents and over 240 pending patent applications that are solely owned or exclusively licensed by atyr. atyr's key programs are currently focused on severe, rare diseases characterized by immune dysregulation
Atyr Pharma Inc executives and other stock owners filed with the SEC include: